News

Diagnostic chip radios results
Enlarge image

ResearchSwitzerland

Diagnostic chip radios results

21.03.2013 - EPFL scientists have developed a tiny, portable personal blood testing implant that sends diagnostic data through mobile phone network.

A tiny subcutaneously implanted blood testing chip can analyse several diagnostic blood parameters and then transmit the results directly to a doctor's computer. The device, developed by researchers at Swiss EPFL in Lausanne is good news for patients with chronic illness such as diabetes or those undergoing chemotherapy, whose blood needs to be monitored permanently. The implant offers an alternative to non-invasive sensors under development, which measure through the skin.

Each of the 5 sensor's surfaces can be covered with an enzyme that allows to detect a blood metabolite or with an antibody that captures specific protein markers.  The few cubic centimetre-large chip's sensors can trace blood glucose, proteins, ATP or organic acids such as lactate simultaneously, Giovanni de Micheli and Sandro Carrara announced at DATE 13, Europe's largest electronics conference.

Potentially, we could detect just about anything," explains De Micheli. "But the enzymes have a limited lifespan." The enzymes currently being tested are good for about a month and a half; that's already long enough for many applications.." After the measurement, the implant emits radio waves over a safe frequency. The patch collects the data and transmits them via Bluetooth to a mobile phone, which then sends them to the doctor over the cellular network.  The implant could be particularly useful in chemotherapy applications.

Currently, oncologists use occasional blood tests to evaluate their patients' tolerance to a particular treatment dosage. Additionally, in patients with chronic disorders, the implants could send alerts even before symptoms emerge, and anticipate the need for medication. The researchers hope the system will be commercially available within 4 years.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/diagnostic-chip-radios-results.html

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

BusinessSwitzerlandGermanyUK

28.10.2014 Swiss pharma company Novartis is selling its influenza vaccines business to Australian biopharma specialist CSL Ltd for US$275m.

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%
  • MORPHOSYS75.99 EUR4.89%

FLOP

  • EPIGENOMICS4.15 EUR-4.38%
  • EVONIK26.20 EUR-2.42%
  • PAION2.80 EUR-2.10%

TOP

  • BIOFRONTERA2.82 EUR28.2%
  • HBM91.50 CHF8.6%
  • EPIGENOMICS4.15 EUR8.4%

FLOP

  • MAGFORCE5.55 EUR-19.6%
  • CO.DON2.65 EUR-15.6%
  • PAION2.80 EUR-13.0%

TOP

  • SANTHERA89.00 CHF2318.5%
  • CO.DON2.65 EUR167.7%
  • WILEX2.25 EUR81.5%

FLOP

  • CYTOS0.17 CHF-95.7%
  • MERCK KGAA71.68 EUR-41.5%
  • 4SC0.98 EUR-41.0%

No liability assumed, Date: 30.10.2014